Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Eli Lilly's LLY short percent of float has risen 5.88% since its last report. The company recently reported that it has 6.10 million shares sold short, which is 0.72% of all regular shares that are ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $757.6 which represents a slight increase of $10.86 or 1.45% from the prior close of $746.74. The stock opened at $747.5 and touched ...